Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity: A multicenter case series.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Catriona Harvey, Kazi Jannatun Nahar, Serigne N. Lo, Tasnia Ahmed, Sheima Farag, Nadia Yousaf, Kate Young, Liselotte Tas, Aafke Meerveld-Eggink, Christian U. Blank, Austin Thomas, Jennifer Leigh McQuade, Bastian Schilling, Douglas Buckner Johnson, Roberto Martin Huertas, Ana Maria Arance, Joanna Lee, Lisa Zimmer, Georgina V. Long, Alexander M. Menzies
Institutions: Royal North Shore Hospital, The University of Sydney, Melanoma Institute Australia, Royal Marsden Hospital, Royal Marsden NHS Foundation Trust, The Netherlands Cancer Institute, The University of Texas Health Science Center at Houston, The University of Texas MD Anderson Cancer Center, Universitätsklinikum Würzburg, Vanderbilt University Medical Center, Hospital Clínic de Barcelona, Sydney Local Health District, Essen University Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281752743